MDGL: Madrigal reports $55.4M Q3 net income; cash $961.8M
Q3 net income $55.4M vs $114.2M loss a year ago; cash and securities $961.8M at Sept 30, 2026, down from $988.6M.
What this filing says
Madrigal Pharmaceuticals filed its quarterly report for the period ended September 30, 2026, showing net income of $55.4 million for the three months, after a net loss over the nine months. The company had $961.8 million in cash, cash equivalents, restricted cash and marketable securities at quarter end, down from $988.6 million at December 31, 2025. For shareholders, the filing shows a profitable quarter alongside continued cumulative losses and a senior secured credit facility of up to $500.0 million.
Key figures
- Q3 net income
- $55.4 million
- Nine-month net loss
- $96.9 million
- Cash and marketable securities
- $961.8 million
- Prior year-end cash and securities
- $988.6 million
- Senior secured credit facility
- up to $500.0 million
Positive for shareholders
- The company reported net income for the three months ended September 30, 2026.
- Revenue is coming from sales of Rezdiffra following FDA accelerated approval and EC conditional marketing authorization.
Negative for shareholders
- The company has incurred losses since inception, including a net loss for the nine months.
- Cash and securities declined from December 31, 2025 to September 30, 2026.
- The company has added a senior secured credit facility of up to $500.0 million.
Written by Quantisnow AI from this filing. Not financial advice.
Key terms
- Pre-funded warrants:
- Securities that let an investor buy shares later at a nominal exercise price, usually issued in place of common shares in an offering.
- Accelerated approval:
- An FDA approval granted early on the basis of a surrogate measure, with the company required to confirm benefit later.
- CMA:
- Conditional marketing authorization, an EC approval allowing sales of a drug while further evidence is collected.
FAQ
Did Madrigal Pharmaceuticals make a profit in the third quarter of 2026?
Yes, the filing reports net income of $55.4 million for the three months ended September 30, 2026.
How much cash did Madrigal Pharmaceuticals have at September 30, 2026?
The company reported $961.8 million in cash, cash equivalents, restricted cash and marketable securities, compared with $988.6 million at December 31, 2025.
Historical context for MDGL
Across the 30 sessions after earlier MDGL headlines, the stock closed higher 17 times and lower 13 times, with a median move of 1.2% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | MDGL | SPY |
|---|---|---|---|
| Nov 3, 2026 | Madrigal Pharmaceuticals Reports Third-Quarter 2026 Financial Results and Provides Corporate Updates | -8.1% | +0.3% |
| Oct 20, 2026 | Madrigal Pharmaceuticals to Release Third-Quarter 2026 Financial Results and Host Webcast on November 3, 2026 | +4.6% | +0.3% |
| Oct 16, 2026 | Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) | -2.2% | -1.1% |
| Oct 6, 2026 | Madrigal Announces Publication in the Journal of Hepatology Demonstrating Consistent Rezdiffra Efficacy Across Common MASH Genetic Risk Variants | +0.6% | +0.5% |
| Sep 24, 2026 | Goldman resumed coverage on Madrigal Pharmaceuticals with a new price target | +0.0% | -0.1% |
| Sep 23, 2026 | Citigroup initiated coverage on Madrigal Pharmaceuticals with a new price target | -1.1% | -0.7% |
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2007
Follow MDGL and get a push notification the moment its next story breaks.